Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
Active, not recruiting · Phase 1 · NCT02203526
Conditions: Primary Central Nervous System Lymphoma
At a glance
- Research payments reported, 2025
- $166,908
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 68
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Isavuconazole (drug), TEDDI (drug), Rituximab (biological), Cytarabine (drug), TEDD (drug), Ibrutinib (Arms 2, 3 and 4) (drug), Methotrexate (drug), Ibrutinib (Arm 1 - Closed with Amendment G) (drug), Ibrutinib (Arm 4) (drug)
- Dates
- Started 2014-08-14; completion 2028-06-15
- Results posted
- Not yet
BACKGROUND: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included high dose methotrexate and radiation treatment. * Most PCNSLs appear to be of activated B-cell (ABC) origin. * Ibrutinib is an inhibitor of Bruton s tyrosine kinase (BTK) and effective for systemic DLBCL of ABC origin. * We propose doing a study in which ibrutinib is combined with a novel chemotherapy platform called dose adjusted temozolomide, etoposide, doxil, dexamethasone, ibrutinib, rituximab (TEDDI-R). OBJECTIVE: \- Identify the maximum …
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $166,908 in research payments for this study in 2025 (2 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Institute of Health $166,908
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.